Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Senthil Lingaratnam

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 6, 2023
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacistsSarah Glewis, Senthil Lingaratnam, Mei Krishnasamy, et al.
Clinical Sarcoma Research|December 11, 2013
Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective reviewJeremy Lewin, Samantha Wieringa, Marnie Collins, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 21, 2026
Pre-emptive <i>DPYD</i> genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patientsSarah Glewis, Senthil Lingaratnam, Tim Spelman, et al.
Internal Medicine Journal|January 11, 2026
An Australasian survey of clinical practices in management of neutropenic fever in adult cancer patients 2023Nikhil Singh, Senthil Lingaratnam, Gabrielle M Haeusler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 29, 2022
A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapySam Maleki, Sarah Glewis, Tsien Fua, et al.
Journal of Pharmaceutical Policy and Practice|August 23, 2024
Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year reviewSenthil Lingaratnam, Safeera Yasmeen Hussainy, Alexandra Murphy, et al.
British Journal of Cancer|March 20, 2022
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosingSarah Glewis, Marliese Alexander, Muhammad N H Khabib, et al.
Clinical and Translational Science|May 3, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancerSenthil Lingaratnam, Mahek Shah, Joseph Nicolazzo, et al.
European Journal of Haematology|May 15, 2013
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxisGabrielle M Haeusler, Monica A Slavin, John F Seymour, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 16, 2023
Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysisMarliese Alexander, Kim Jachno, Kelly-Anne Phillips, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 6, 2023
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacistsSarah Glewis, Senthil Lingaratnam, Mei Krishnasamy, et al.
Clinical Sarcoma Research|December 11, 2013
Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective reviewJeremy Lewin, Samantha Wieringa, Marnie Collins, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 21, 2026
Pre-emptive <i>DPYD</i> genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patientsSarah Glewis, Senthil Lingaratnam, Tim Spelman, et al.
Internal Medicine Journal|January 11, 2026
An Australasian survey of clinical practices in management of neutropenic fever in adult cancer patients 2023Nikhil Singh, Senthil Lingaratnam, Gabrielle M Haeusler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 29, 2022
A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapySam Maleki, Sarah Glewis, Tsien Fua, et al.
Journal of Pharmaceutical Policy and Practice|August 23, 2024
Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year reviewSenthil Lingaratnam, Safeera Yasmeen Hussainy, Alexandra Murphy, et al.
British Journal of Cancer|March 20, 2022
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosingSarah Glewis, Marliese Alexander, Muhammad N H Khabib, et al.
Clinical and Translational Science|May 3, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancerSenthil Lingaratnam, Mahek Shah, Joseph Nicolazzo, et al.
European Journal of Haematology|May 15, 2013
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxisGabrielle M Haeusler, Monica A Slavin, John F Seymour, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 16, 2023
Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysisMarliese Alexander, Kim Jachno, Kelly-Anne Phillips, et al.
Pageof 3